Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, today reported financial results and key ...

In April 2024, Entera announced that the Journal of Bone and Mineral Research (JBMR) published EB613 placebo controlled Phase 2 Trial results, highlighting its dual mechanism of action and rapid ...

The program combines OPKO’s oxyntomodulin analog (OPK-88006) and Entera’s N-Tab technology. The companies expect to file an Investigational New Drug application with the U.S. Food and Drug ...

The programme unites Opko's long-acting oxyntomodulin (OXM) analogue, OPK-88006 and Entera's N-Tab technology. Opko will hold 60% and Entera 40% ownership interests. The partnership will account ...

The programme unites Opko’s long-acting oxyntomodulin (OXM) analogue, OPK-88006 and Entera’s N-Tab technology. Opko will hold 60% and Entera 40% ownership interests. The partnership will account for ...

OPKO, whose long-acting oxyntomodulin analog is the basis of the drug candidate, will shoulder 60% of the costs and hold the same percentage of pro-rata ownership interest. Entera, meanwhile, will ...

The treatment, a once-daily tablet, combines OPKO's long-acting oxyntomodulin analog (OPK-88006) with Entera's N-Tab technology. Favorable preclinical data was reported in September 2024 ...

The program combines OPKO’s proprietary long-acting oxyntomodulin analog and Entera’s proprietary N-Tab technology. Favorable pharmacodynamic, pharmacokinetic and bioavailability data in vivo ...